Discover a study that has revealed a new potential mechanism of understanding inflammation in ulcerative colitis.

Johnson & Johnson (J&J) has shared positive long-term results from a phase 3 trial of its dual-acting IL-23 inhibitor Tremfya ...

The research also predicts inflammatory bowel disease diagnoses will likely double in Aotearoa in the next 20 years.

To evaluate the therapeutic value of mirikizumab in IBD, researchers conducted a systematic review and meta-analysis of ...

For an accessible version of this Press Release, please visit On track for 30% operating profit margin by 2027 in line with ...

Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1st Conference call ...

Women with the autoimmune diseases rheumatoid arthritis, lupus or systemic sclerosis may have a higher rate of death related to cardiovascular disease than men with the autoimmune diseases, according ...

CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading ...

Women with any of three common types of autoimmune disease may face a higher rate of death linked to heart disease and stroke ...

Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1stConference call t ...

NET LOSS FORECAST: Takeda is expected to post a net loss of 81.7 billion yen, equivalent to $573.7 million, for the three months ended March, according to a Visible Alpha poll of analysts. That ...

Express Scripts, Cigna, UnitedHealthcare, CVS Caremark and Optum Rx are among the payers that have added Yesintek to their ...